✦ LIBER ✦

P41 A randomized 2 × 2 biomarker trial of low-dose tamoxifen and fenretinide in premenopausal women at-high risk for breast cancer

✍ Scribed by S. Mora; C. Robertson; A. Guenieri-Gonzaga; M. Cazzaniga; H. Johansson; D. Serrano; M. Gulisano; E. Cassano; D. Franchi; A. Decensi

Book ID: 118621917
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 119 KB
Volume: 2
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(04)90156-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Circulating hormones and breast cancer r

Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide

✍ Johansson, Harriet; Bonanni, Bernardo; Gandini, Sara; Guerrieri-Gonzaga, Aliana; 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 390 KB

P1 Circulating adiponectin levels as a p

P1 Circulating adiponectin levels as a predictive factor of breast cancer in a double-blind 2×2 phase II trial of low-dose tamoxifen and fenretinide for breast cancer prevention

✍ A. Guerrieri Gonzaga; S. Gandini; H. Johansson; D. Macis; P. Magni; E. Dozio; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Randomized trial of low-dose interleukin

Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-γ after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer

✍ Vahdat, L T; Cohen, D J; Zipin, D; Lo, K S; Donovan, D; Savage, D; Tiersten, A; 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 155 KB

Relationships between CYP2D6 phenotype,

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

✍ Sestak, I; Kealy, R; Nikoloff, M; Fontecha, M; Forbes, J F; Howell, A; Cuzick, J 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 189 KB

A randomized phase III trial of adjuvant

A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study

✍ J. Andersen; M. Andersson; K.W. Andersen; P. Dombemowsky; H.T. Mouridsen; C. Ros 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 300 KB

MP56-19 LONG TERM RESULTS OF A DOUBLE-BL

MP56-19 LONG TERM RESULTS OF A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF INTERFERON ALPHA-2B AND LOW DOSE BCG IN PATIENTS WITH HIGH RISK NON-MUSCLE-INVASIVE BLADDER CANCER

✍ Esuvaranathan, Kesavan; Tham, Sin Mun; Ravuru, Mohan; Kamaraj, Revathi; Ng, Tze 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 137 KB